Ultragenyx Reports Positive Long-Term Data for UX111 Gene Therapy, Bolstering BLA Resubmission
Summary
Ultragenyx reported strong long-term clinical data for its UX111 gene therapy for Sanfilippo syndrome type A, showing significant functional and biomarker improvements, which were included in its recently resubmitted BLA to the FDA.
Key Events
-
Positive Long-Term Clinical Data for UX111
New data from clinical studies evaluating UX111 gene therapy for Sanfilippo syndrome type A (MPS IIIA) demonstrated substantial and durable biomarker improvements and meaningful functional benefits compared to natural history.
-
Significant Functional Improvements Observed
Children under two years or with earlier-stage disease showed a +23.2 point treatment effect in Bayley-III cognitive raw scores. Improvements were also noted in receptive and expressive communication, and fine and gross motor skills.
-
Functional Skill Retention in Later-Stage Children
Patients with more advanced disease showed retention of functional abilities (communication, ambulation, self-feeding) that exceed typical decline patterns in untreated children.
-
Favorable Safety Profile Confirmed
UX111 was generally well-tolerated across all doses, with treatment-related adverse events being mostly mild or moderate and resolving spontaneously.
Analysis
Ultragenyx Pharmaceutical Inc. announced compelling long-term clinical data for its UX111 gene therapy, which targets Sanfilippo syndrome type A (MPS IIIA), a severe neurodegenerative disorder. The data demonstrates significant and durable improvements in biomarkers and functional abilities across various age groups and disease stages, compared to natural history. This positive outcome, coupled with a favorable safety profile, strengthens the company's Biologics License Application (BLA) for UX111, which was recently resubmitted to the FDA. The anticipated PDUFA date in the third quarter of 2026 marks a critical milestone for potential accelerated approval, offering hope for patients with this fatal condition.
At the time of this filing, RARE was trading at $25.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.41 to $46.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.